A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects

Table 4 Analysis of change (delta values) of outcomes at study time points ^a

Test	Treatment	Delta value T1^bversus T2^c	Delta value T2 versus T3^d	Delta value T1 versus T3
ADAS-Cog ^e	IFNβ 1a	0.144 ± 1.16	−2.17 ± 1.01 (p = 0.031)	−2.02 ± 1.58
ADAS-Cog ^e	Placebo	2.25 ± 1.05	−2.78 ± .1.02	−0.52 ± 1.86
MMSE ^f	IFNβ 1a	0.78 ± 0.52	−1.81 ± 0.69 (p = 0.037)	−1.02 ± 1.03
MMSE ^f	Placebo	0.73 ± 0.98	−1.68 ± 0.76	−0.95 ± 1.0
ADAS-NonCog ^g	IFNβ 1a	−0.26 ± 0.53	−0.84 ± 0.35	−1.10 ± 0.65
ADAS-NonCog ^g	Placebo	0.86 ± 0.75	−2.0 ± 1.099	−1.13 ± 1.26
PSMS ^h	IFNβ 1a	0.31 ± 0.23	1.05 ± 0.66 (p = 0.0459)	1.36 ± 0.76 (p = 0.025)
PSMS ^h	Placebo	0.6 ± 0.6	−0.13 ± 0.29	0.46 ± 0.33
GDS ⁱ	IFNβ 1a	0.42 ± 0.94	−1.10 ± 0.79	−0.68 ± 1.35
GDS ⁱ	Placebo	2.0 ± 1.34	1.57 ± 0.83 (p = 0.0418)	3.57 ± 1.24 (p = 0.009)
Global DS ^j	IFNβ 1a	−0.05 ± 0.17	−0.21 ± 0.12	−0.26 ± 0.18
Global DS ^j	Placebo	−0.13 ± 0.13	−0.2 ± 0.10	−0.33 ± 0.15
IADL ^k	IFNβ 1a	0.26 ± 0.34	0.94 ± 0.37 (p = 0.0306)	1.20 ± 0.59 (p = 0.041)
IADL ^k	Placebo	0.6 ± 0.36	−0.06 ± 0.18	0.53 ± 0.36

^aValues are shown as means ± SEM; Negative change indicates worsening of condition. In brackets are reported p values (by arm) when statistically significant. ^bT1 = baseline (week 0); ^cT2 = end of treatment (week 28); ^dT3 = follow-up (week 54). ^eADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; ^fMMSE, Mini Mental State Examination; ^gADAS-Non-Cog, Alzheimer’s Disease Assessment Scale-Non-Cognitive Section; ^hPSMS, Physical Self-Maintenance Scale; ⁱGDS, Geriatric Depression Scale; Global, ^jGlobal Deterioration Scale (DS) for Assessment of Primary Degenerative Dementia; ^kIADL, Instrumental Activities of Daily Living Scale.

ISSN: 1742-2094